- In 2015, the only action taken after the European review of ivabradine was the adoption of some restrictions on its use and some precautionary measures, despite the fact that this drug offers no advantages over other options and is known to have sometimes fatal cardiovascular adverse effects.
- In practice, ivabradine has more harms than benefits in both angina and heart failure.
- Since European health authorities have not yet decided to withdraw this drug from the market, it is advisable to simply avoid it.
Full text available for free download.
©Prescrire 1 November 2015